In addition, alpha(2)-adrenergic receptor antagonists, 5-HT(1A) agonists, and astrocyte-modulating agents are also used for treating PD-related dyskinesias or dyskinesias associated with l-DOPA 86. Here, HTR1A is linked to drug-induced dyskinesia.